Related Experiment Video

Updated: May 20, 2025

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.4K

The MicroRNA miR-454 and the mediator complex component MED12 are regulators of the androgen receptor pathway in

Juan Guzman1,2, Martin Hart3, Katrin Weigelt1,2

  • 1Department of Urology and Pediatric Urology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.

Scientific Reports
|March 26, 2025
PubMed

Insights

MED12 knockdown and miR-454-3p offer potential strategies against enzalutamide-resistant prostate cancer (PCa). MED12 targeting reduced cell viability, suggesting its promise for future PCa therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer (PCa) resistance to anti-androgen therapies like enzalutamide presents a significant clinical challenge.
  • Enzalutamide-resistant PCa cell lines (LNCaP Abl EnzR, DuCaP EnzR) serve as valuable in vitro models for studying resistance mechanisms.

Purpose of the Study:

  • To investigate strategies for reducing Androgen Receptor (AR), AR-V7, and c-Myc expression in enzalutamide-resistant PCa.
  • To explore the therapeutic potential of targeting MED12 and miR-454-3p in this context.

Main Methods:

  • Utilized MED12 knockdown (siMED12) and synthetic miR-454-3p transfection in enzalutamide-resistant PCa cell lines.
  • Assessed protein expression levels of AR, AR-V7, and c-Myc.
  • Evaluated cellular effects, including cell viability.

Main Results:

  • MED12 knockdown decreased AR, AR-V7, and c-Myc protein levels.
  • miR-454-3p targeted AR and AR-V7, reducing AR expression in both cell lines and c-Myc/AR-V7 in DuCaP EnzR cells.
  • siMED12, but not miR-454-3p, reduced cell viability; no additive effects were observed with combined treatment.

Conclusions:

  • MED12 is identified as a potential therapeutic target for overcoming enzalutamide resistance in prostate cancer.
  • miR-454-3p directly targets AR and AR-V7, revealing novel molecular mechanisms in PCa progression and resistance.
Keywords:
Androgen receptorAndrogen receptor splice variant 7Cell viabilityMED12MiRNAProstate cancerProtein expressionc-Myc

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
69.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K